All News

ViewPoints: Don’t hate Merck & Co., hate the game

Ref: ViewPoints Desk

Tags: ViewPoints J&J Merck & Co. Novartis Pfizer FDA

ViewPoints: Agios gears up for a Celgene-free commercial launch

Ref: ViewPoints Desk

Tags: ViewPoints Agios Pharmaceuticals Celgene Abbott Leukaemias FDA Marketing & Sales Medical Affairs Tibsovo IDHIFA

ViewPoints: PTC pivots into gene therapy, but away from DMD

Ref: ViewPoints Desk

Tags: ViewPoints Agilis Biotherapeutics PTC Therapeutics FDA Mergers & Acquisitions AGIL-AADC

BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma

Ref: GlobeNewswire

Tags: Press Release BeiGene Lymphomas Clinical Research (R&D)Tislelizumab

BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM)

Ref: GlobeNewswire

Tags: Press Release BeiGene Lymphomas FDA Clinical Research (R&D) Regulatory Affairs ibrutinib Zanubrutinib

ViewPoints: Roche jumps but falls shy of the bar set by Merck & Co. in lung cancer

Ref: ViewPoints Desk

Tags: ViewPoints Merck & Co. Roche Lung Cancer Clinical Research (R&D) Medical Affairs Keytruda Tecentriq

KOL Views Results: Invokana may get boost from CREDENCE but benefit likely to be shared by SGLT-2 class, says leading endocrinologist

Ref: KOL Views Desk

Tags: KOL Views Results AstraZeneca Boehringer Ingelheim J&J Lilly Novo Nordisk Diabetes FDA Marketing & Sales Medical Affairs Farxiga Invokana Jardiance semaglutide

Bitter pill: No cure in sight for an ailing pharmacy sector

Ref: Independent.ie

Tags: NewsPoints McKesson Corporate Affairs

Johnson and Johnson to offer first TB drug in 40 years for $900

Ref: The Economic Times

Tags: NewsPoints J&J Respiratory Infections Corporate Affairs Marketing & Sales Bedaquiline

Rabies scandal rocks China’s vaccine industry

Ref: Global Times

Tags: NewsPoints China Immunisation CFDA Marketing & Sales Regulatory Affairs rabies vaccine